Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07287644 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Bluefin Biomedicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
- 4
- Study locations
NCT07287644: Recruiting Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Bluefin Biomedicine.
NCT07287644 is a Phase 2 study of Hidradenitis Suppurativa (HS) that is actively recruiting participants, run by Bluefin Biomedicine. The registered enrollment target is 210 participants, above the 163-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (29% higher). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07287644, a Phase 2 study of Hidradenitis Suppurativa (HS), is actively recruiting participants, sponsored by Bluefin Biomedicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Primary Outcome
To evaluate the efficacy of BFB759 in adult male and female participants with HS as measured by the change in the number of abscesses and inflammatory nodules (AN count).
Conditions Studied
Interventions
- BIOLOGICAL BFB759
- OTHER Placebo for BFB759
Study Locations (4)
Florida
- Skin Care Research - Boca Raton
- Ziaderm Research LLC - North Miami Beach
- Clinical Trials Management, LLC - Tampa
Louisiana
- Clinical Trials Management, LLC - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 2 |
What NCT07287644 shows while recruiting
NCT07287644 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, above the 163-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (29% higher).
The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 2 interventions - of which BFB759 is the first listed.
NCT07287644 reports a single indexed study location in Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT07287644 about?
NCT07287644 is a clinical study titled "A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa". This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
What is the current status of trial NCT07287644?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2025-11-03. Estimated completion is 2027-08-01.
What conditions does trial NCT07287644 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).
What interventions are being tested in trial NCT07287644?
The interventions under investigation include: BFB759 (BIOLOGICAL), Placebo for BFB759 (OTHER).
Who is sponsoring clinical trial NCT07287644?
This trial is sponsored by Bluefin Biomedicine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07287644 being conducted?
This trial has 4 study locations across Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa (HS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07287644's enrollment target sits among peer trials
210 4th of 12 higher than 9 of 12 other Hidradenitis Suppurativa (HS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa (HS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
RECRUITING · Phase 2
-
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RECRUITING · Phase 2
-
The Safety and Efficacy of Roflumilast Foam in HS
RECRUITING · Phase 2
-
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
Hidradenitis Suppurativa Wound Care
COMPLETED · Phase 2
-
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI